Texas A&M Sensor Material Cuts Glucose Monitoring Cost

A sensing material that costs roughly one-tenth as much as the standard alternative performed just as well inside an experimental injectable glucose sensor, Texas A&M University researchers reported on November 3, 2026. The study ran in ACS Measurement Science Au. The sensor itself is still a laboratory proof of concept.

Continuous glucose monitors give people with diabetes a running picture of their blood sugar, and more than 500 million people worldwide live with the disease. Today's monitors rely on patches and filaments that wear out and cost money every few weeks. A sensor that sits under the skin and lasts would attack both problems at once.

The Texas A&M platform doesn't use enzymes at all. It pairs concanavalin A, a protein that binds sugar, with a fluorescent sugar compound, and reads glucose through near-infrared light. As glucose rises, it competes for the protein's binding sites and the fluorescent signal changes, which lets the sensor estimate the glucose level.

The cost finding sits inside that chemistry. The team compared glucose-binding compounds and found that beta-mannopentaose matched the performance of alpha-mannopentaose, the compound earlier versions used, at about a tenth of the price. One ingredient doesn't set a device's final cost, but a tenfold gap on a core material is where cheaper designs start.

The chemistry rides inside a small hydrogel rod, about 2.5 millimeters wide and 11 millimeters long, designed to be injected into tissue under the skin. In lab testing the sensor tracked glucose from 25 to 400 milligrams per deciliter, a range that covers low, normal and high readings. After seven days the hydrogel still held more than 94 percent of its sensing mixture.

The limits are plain in the paper, by Sayantan Tripathy and co-authors. Testing ran in artificial interstitial fluid under laboratory conditions, not in patients, and seven days of retention isn't the months of stable performance an implanted monitor would need. The researchers say the technology needs substantial development and testing before anyone can consider clinical use.

The work comes out of the National Science Foundation's PATHS-UP engineering research center, which targets health technology for under-resourced communities. That mission explains the obsession with a cheaper molecule: a monitor only widens access if clinics and patients can afford to keep using it.

No timeline exists for a patient version, and nobody should read one into this result. What the study establishes is narrower and still useful: the expensive ingredient in this sensor design isn't load-bearing. The next tests, in living tissue over longer stretches, will decide whether the cheap version survives contact with a body.